CytomX Therapeutics (CTMX) Enterprise Value (2014 - 2026)
CytomX Therapeutics (CTMX) posted Enterprise Value of -$346.7 million for Q1 2026, down 152.97% on a QoQ basis from -$137.1 million in Q4 2025, and down 334.0% year-over-year from $148.2 million in Q1 2025.
CytomX Therapeutics (CTMX) Enterprise Value (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$346.7 million for Q1 2026.
- Quarterly Enterprise Value fell 334.0% year-over-year to -$346.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$346.7 million (down 334.0% YoY) and the FY2025 annual result came in at -$137.1 million, down 36.2% from the prior year.
- Enterprise Value was -$346.7 million for Q1 2026 at CytomX Therapeutics, down from -$137.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$79.9 million in Q1 2025 and bottomed at -$346.7 million in Q1 2026.
- A 5-year average of -$176.7 million and a median of -$174.5 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value soared 46.84% — and 2026, when it plunged 334.0%.
- CytomX Therapeutics' Enterprise Value stood at -$193.6 million in 2022, then gained by 9.88% to -$174.5 million in 2023, then surged by 42.34% to -$100.6 million in 2024, then plunged by 36.2% to -$137.1 million in 2025, then slumped by 152.97% to -$346.7 million in 2026.
- Business Quant data shows CTMX's Enterprise Value at -$346.7 million in Q1 2026, -$137.1 million in Q4 2025, and -$143.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -346.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -346.71 Mn |
| Dec 31, 2025 | -137.05 Mn |
| Sep 30, 2025 | -143.63 Mn |
| Jun 30, 2025 | -158.09 Mn |
| Mar 31, 2025 | -79.89 Mn |
| Dec 31, 2024 | -100.62 Mn |
| Sep 30, 2024 | -117.59 Mn |
| Jun 30, 2024 | -137.18 Mn |
| Mar 31, 2024 | -150.28 Mn |
| Dec 31, 2023 | -174.51 Mn |
| Sep 30, 2023 | -194.11 Mn |
| Jun 30, 2023 | -180.86 Mn |
| Mar 31, 2023 | -204.50 Mn |
| Dec 31, 2022 | -193.65 Mn |
| Sep 30, 2022 | -194.29 Mn |
| Jun 30, 2022 | -228.17 Mn |
| Mar 31, 2022 | -262.53 Mn |
| Dec 31, 2021 | -305.23 Mn |
| Sep 30, 2021 | -236.29 Mn |
| Jun 30, 2021 | -266.18 Mn |